Elanco Animal Health Conference Call Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date**: February 26, 2026 - **Speakers**: Jeff Simmons (President and CEO), Bob VanHimbergen (Executive VP and CFO) Key Points Industry and Market Position - The animal health industry is experiencing positive trends, particularly in pet care and protein sectors, with Elanco positioned well within these markets [5][6] - Elanco's strategy focuses on growth, innovation, and cash generation, aiming to be a consistent and reliable performer [5][6] Financial Performance - Elanco reported strong Q4 results, exceeding expectations in adjusted EBITDA, revenue, and EPS [6] - Guidance for fiscal 2036 includes: - Mid-single-digit top-line growth - High single-digit EBITDA growth - Low double-digit EPS growth - Deleveraging to low threes by year-end [8][22] Innovation and Product Pipeline - Elanco's innovation pipeline is robust, with a focus on products like Zenrelia and Befrena, which are expected to drive future growth [10][12] - Zenrelia has shown strong market uptake, achieving 40% market share in Brazil and significant growth in the U.S. [13][15] - The company plans to increase investment in Zenrelia due to its positive performance and demand [14] Competitive Landscape - Elanco anticipates competitive responses from companies like Zoetis and Merck, but believes its product efficacy will maintain its market position [62][67] - The entry of new competitors, such as Merck's NUMELVI, is factored into Elanco's guidance, with expectations of continued market share growth [30][34] Pricing Strategy - Elanco has implemented a price increase of 2% in 2025, with expectations for further price uplift in 2026 due to new product launches [74][76] - The company emphasizes that market share gains are driven by product efficacy rather than pricing alone [74] Distribution Relationships - Elanco maintains strong relationships with major distributors, which are expected to provide a competitive advantage moving forward [78][80] - The company has a unique buy-sell model that allows for better value creation and demand generation [78] Long-term Outlook - Elanco expects to see EBITDA margins improve by 200 to 350 basis points by 2028, driven by volume leverage and a favorable product mix [88] - The Ascend initiative is expected to contribute significantly to operational efficiency and margin improvement [88] Additional Insights - The company is focused on maintaining a balanced approach to investment in innovation and operational efficiency, ensuring long-term growth [81][85] - Elanco's omnichannel approach is highlighted as a key strategy to enhance customer engagement and compliance in pet care [41] Conclusion Elanco Animal Health is positioned for growth in the animal health market, driven by a strong innovation pipeline, effective pricing strategies, and robust distribution relationships. The company is optimistic about its future performance, with a focus on maintaining product efficacy and market share amidst increasing competition.

PresentationI would now like to turn the call over to Allison Beach, Director of Public Relations. Please go ahead.Good morning, ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ashford Hospitality Trust Fourth Quarter 2025 Results Conference Call. [Operator Instructions]Allison BeachDirector of Public Relations Good morning, and welcome to today's conference call to review results for ...

Moody's Corporation (NYSE:MCO) is among the 20 Best Investments in 2026. UBS Maintains Neutral on Moody's Corporation (MCO) Following Q4 Earnings Release Moody’s Corporation (NYSE:MCO) is among the best investments on our list. TheFly reported on February 19 that UBS reduced its price target on MCO to $490 from $515 and maintained a Neutral rating, reflecting adjustments to its model after the company’s fourth-quarter earnings release. On February 18, 2026, Moody's Corporation (NYSE:MCO) released its f ...

Group 1 - Jefferies has lowered its price target for Intuit Inc. (INTU) to $650 from $850 while maintaining a Buy rating, anticipating solid results in fiscal Q2 despite a "seasonally light" period [1] - The potential upside for Intuit is driven by Credit Karma, with favorable momentum among card issuers [1] - Intuit has introduced a major update to its Consumer Group with the TurboTax "Done-For-You" experience, utilizing Agentic AI for about 90% of standard tax form data entry [2] Group 2 - The new TurboTax experience is supported by nearly 600 Expert Offices and 20 new immersive stores, enhancing customer service [2] - A partnership with Uber Advertising will offer consumers a complimentary ride up to $25 to visit local tax experts, improving accessibility [3] - The program aims to streamline tax preparation, eliminate obstacles, and provide a more effective, individualized, and secure experience for filers [3] Group 3 - Intuit Inc. provides financial, accounting, and tax software solutions, including QuickBooks, TurboTax, and Mint, helping individuals and businesses manage finances efficiently [4]

Robinhood Markets, Inc. (NASDAQ:HOOD) is among the 20 Best Investments in 2026. Goldman Sachs Adjusts Robinhood Markets, Inc. (HOOD) Price Target, Cites Strong Early-Year Metrics Robinhood Markets, Inc. (NASDAQ:HOOD) is among the best investments. TheFly reported on February 20 that Goldman Sachs lowered its price target for HOOD to $111 from $130 while maintaining a Buy rating. With funded accounts climbing 9% year over year to 27.2 million, equity and cryptocurrency trading volumes rising 57% and 12%, ...

MercadoLibre, Inc. (NASDAQ:MELI) is among the 20 Best Investments in 2026. Wedbush Notes MercadoLibre, Inc. (MELI) Well-Positioned Going Into Q4 MercadoLibre, Inc. (NASDAQ:MELI) tops our list for being one of the best investments. TheFly reported on February 17 that Wedbush adjusted its price target for MELI to $2,600 from $2,700 while keeping an Outperform rating on the stock. The firm supports MELI as a top choice for 2026 and believes it is well-positioned going into the fourth quarter, but it points ...

Veeva Systems Inc. (NYSE:VEEV) is among the 20 Best Investments in 2026. Veeva Systems Inc. (VEEV) Launches eSource to Streamline Clinical Trial Data The fifth stock on our list of best investment stocks is Veeva Systems Inc. (NYSE:VEEV). TheFly reported on February 20 that UBS reduced its price target on VEEV to $200 from $280 while maintaining a Neutral rating on the stock. Veeva Systems Inc. (NYSE:VEEV) made a significant announcement on January 29 when it unveiled Veeva eSource, a new application w ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 20 Best Investments in 2026. BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is next on our list. TheFly reported on February 18 that Wells Fargo & Company increased its price target for BMRN from $70 to $75 while keeping an Overweight rating. The firm believes the upcoming Transcon-CNP PDUFA may mark the final negative catalyst for BMRN, and its sum ...

Sprouts Farmers Market, Inc. (NASDAQ:SFM) is among the 20 Best Investments in 2026. Goldman Sachs Notes Slower-Than-Expected Early-Year Comps for Sprouts Farmers Market, Inc. (SFM) The seventh stock on our list of best investments is Sprout Farmers Market, Inc. (NASDAQ:SFM). TheFly reported on February 20 that Goldman Sachs lowered its price target on SFM to $111 from $130 and kept a Buy rating. Despite falling short on gross margins, the company's fourth-quarter results surpassed comparable-store sales ...

Dell Technologies Inc. (NYSE:DELL) is among the 20 Best Investments in 2026. IT Hardware Sector Weakness Drives Morgan Stanley's Dell Technologies Inc. (DELL) Downgrade Dell Technologies Inc. (NYSE:DELL) is on our list of best investment stocks. TheFly reported on February 18 that Morgan Stanley reduced its price target on DELL  from $111 to $101and gave it an Underweight rating. The firm anticipates a solid, though not exceptional, performance for the January quarter and upcoming April guidance from of ...